Citi analyst Samantha Semenkow lowered the firm’s price target on Immunovant (IMVT) to $57 from $58 and keeps a Buy rating on the shares. The firm, which continues to believe IMVT-1402 has “blockbuster potential” across multiple indications, updated its model to account for fiscal Q1 actuals. The firm’s lower target is driven by higher expected operating expenses related to IMVT-1402 clinical development, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT: